REGULATORY

NHI Price Revision in FY2017 and Annual NHI Price Revision Should Be Discussed Separately: Shirakawa

June 11, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council’s (Chuikyo) Expert Subcommittee on NHI Drug Pricing Affairs discussed annual NHI drug price revisions at a meeting on June 10. Healthcare provider representative Yoshihiro Abe, executive director, Japan Pharmaceutical Association, initiated the discussion, saying,…

To read the full story

FY2016 Drug Pricing Reform
August 18, 2015
Abe of JPA Proposes Exempting Ordinary Pharmacies from Medical Fee Cut Rule: Chuikyo
June 12, 2015
Chuikyo Begins Discussions on FY2016 NHI Pricing Reform; Drug Pricing Organization to Present Views at Next Meeting
June 11, 2015

REGULATORY

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
Chuikyo OKs 3.5% Minimum NHI Price Hike, Sets Grace Period for New AG Pricing
January 19, 2026
Antivirals, Cancer Drugs Flagged in PMDA Risk Review
January 19, 2026
Bosulif, 4 Other Drugs Escape April Re-Pricing as “Spillover” Scrapped; Lixiana, Entresto Brace for Cuts
January 19, 2026
Japan Panel to Review Pfizer’s Cancer Med Tukysa on January 29
January 16, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…